Physician profile
Christopher Randolph
NPI 1437142551
$268,916.86
in general payments reported to CMS, 2019-2025
39 companies · $19K in 2025
The $19K reported for 2025 was more than what 91% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $89K · 2020: $50K · 2021: $46K · 2022: $40K · 2023: $16K · 2024: $7,713 · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Consulting Fee: $11K · Food and Beverage: $6,055 · Travel and Lodging: $2,674 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23,809.00 |
| Consulting Fee | $10,678.13 |
| Food and Beverage | $6,055.06 |
| Travel and Lodging | $2,673.93 |
| Education | $110.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $86,502.75 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $27,305.75 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $25,900.46 | 2019-2025 | Tezspire, Airsupra, Breztri |
| Csl Behring | $22,255.26 | 2019-2025 | Andembry, Haegarda, Hizentra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18,142.90 | 2019-2022 | |
| Optinose US, INC. | $15,728.71 | 2019-2025 | |
| Grifols USA, LLC | $15,638.18 | 2019-2025 | Xembify |
| Regeneron Healthcare Solutions, INC. | $15,551.10 | 2019-2025 | Dupixent |
| Amgen INC. | $10,642.41 | 2021-2025 | Tezspire |
| Pfizer INC. | $9,294.08 | 2019-2025 | |
| Shire North American Group INC | $6,219.52 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $4,201.74 | 2021 | |
| Pharming Healthcare, INC. | $3,323.74 | 2019-2025 | Ruconest |
| Biocryst US Sales Co., LLC | $3,203.40 | 2021-2025 | Orladeyo |
| Cycle Pharmaceuticals INC | $1,439.92 | 2024-2025 | Sajazir, Sajazir |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Randolph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.